Stable serum miRNA profiles as potential tool for non-invasive lung cancer diagnosis

Circulating microRNAs in human serum have increasingly been recognized as stable markers for cancer detection. However, there is still a lack of miRNome wide studies over a long period of time with respect to pathogenic processes. We obtained serum samples from the janus serum bank collected prior and after diagnosis of lung cancer. We analyzed the abundance of 904 miRNAs in serum from eight cancer patients at three time points and from six healthy control individuals. Based on the identified miRNA signatures, hierarchical clustering and a self-organizing map identified three major clusters including one cluster containing most of the of the pre-diagnostic samples, a second cluster with mainly post-diagnostic samples, and a third cluster with mainly control samples. Correlation analyses showed that although the profiles were generally stable over several years, most obvious changes of the miRNA pattern seem to occur at a time close to diagnosis. Our findings support the idea that a developing lung cancer might be detectable years prior to diagnosis through a specific miRNA signature and that this signature changes during tumor development.

[1]  Raghu Kalluri,et al.  Cancer without disease , 2004, Nature.

[2]  Takahiro Ochiya,et al.  Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis , 2010, Cancer science.

[3]  Sandra B. Munro,et al.  Detection of Cancer with Serum miRNAs on an Oligonucleotide Microarray , 2009, PloS one.

[4]  Crislyn D'Souza-Schorey,et al.  Microvesicles: mediators of extracellular communication during cancer progression , 2010, Journal of Cell Science.

[5]  Hans-Peter Lenhof,et al.  GeneTrailExpress: a web-based pipeline for the statistical evaluation of microarray experiments , 2008, BMC Bioinformatics.

[6]  Kenneth M. Yamada,et al.  Cell–matrix adhesion , 2007, Journal of cellular physiology.

[7]  Yasushi Okuno,et al.  MicroRNA: biogenetic and functional mechanisms and involvements in cell differentiation and cancer. , 2006, Journal of pharmacological sciences.

[8]  Sam Griffiths-Jones,et al.  miRBase: the microRNA sequence database. , 2006, Methods in molecular biology.

[9]  Eckart Meese,et al.  miRNAs in lung cancer - Studying complex fingerprints in patient's blood cells by microarray experiments , 2009, BMC Cancer.

[10]  Susumu Goto,et al.  KEGG for representation and analysis of molecular networks involving diseases and drugs , 2009, Nucleic Acids Res..

[11]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[12]  Q. Cui,et al.  An Analysis of Human MicroRNA and Disease Associations , 2008, PloS one.

[13]  G. Calin,et al.  MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. , 2009, Expert opinion on biological therapy.

[14]  R. Scheuermann,et al.  Cancer dormancy: isolation and characterization of dormant lymphoma cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Chunxiang Zhang,et al.  A translational study of circulating cell-free microRNA-1 in acute myocardial infarction. , 2010, Clinical science.

[16]  Sonja Vorwerk,et al.  Microfluidic-based enzymatic on-chip labeling of miRNAs. , 2008, New biotechnology.

[17]  Anton J. Enright,et al.  Human MicroRNA Targets , 2004, PLoS biology.

[18]  R. Stephens,et al.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. , 2006, Cancer cell.

[19]  Zhihua Li,et al.  Regulatory Circuit of Human MicroRNA Biogenesis , 2007, PLoS Comput. Biol..

[20]  Y. Hochberg A sharper Bonferroni procedure for multiple tests of significance , 1988 .

[21]  Hiroyuki Ogata,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..

[22]  N. Rajewsky,et al.  Silencing of microRNAs in vivo with ‘antagomirs’ , 2005, Nature.

[23]  Julian L. Griffin,et al.  Metabolic profiles of cancer cells , 2004, Nature Reviews Cancer.

[24]  David B Jackson,et al.  Serum-based microRNAs: Are we blinded by potential? , 2009, Proceedings of the National Academy of Sciences.

[25]  Xi Chen,et al.  Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Hans-Peter Lenhof,et al.  Multiple Sclerosis: MicroRNA Expression Profiles Accurately Differentiate Patients with Relapsing-Remitting Disease from Healthy Controls , 2009, PloS one.

[27]  Yariv Yogev,et al.  Serum MicroRNAs Are Promising Novel Biomarkers , 2008, PloS one.

[28]  M. Kogevinas,et al.  Levelling-off of the risk of lung and bladder cancer in heavy smokers: an analysis based on multicentric case-control studies and a metabolic interpretation. , 2000, Mutation research.

[29]  T. Dalmay,et al.  MicroRNAs and the hallmarks of cancer , 2006, Oncogene.

[30]  X. Chen,et al.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases , 2008, Cell Research.

[31]  Christina Backes,et al.  GeneTrail—advanced gene set enrichment analysis , 2007, Nucleic Acids Res..

[32]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[33]  Y. Benjamini,et al.  Controlling the false discovery rate in behavior genetics research , 2001, Behavioural Brain Research.

[34]  Douglas D. Taylor,et al.  Exosomal microRNA: a diagnostic marker for lung cancer. , 2008, Clinical lung cancer.